Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. develops investigational therapies for genetically driven neuromuscular diseases using its FORCE platform, which is designed to deliver payloads to muscle tissue and the central nervous system. Company news centers on clinical programs in Duchenne muscular dystrophy and myotonic dystrophy type 1, including z-rostudirsen, z-basivarsen, the DELIVER, ACHIEVE and HARMONIA studies, and preclinical work in additional neuromuscular diseases.
Recurring updates include clinical data presentations, FDA interactions and designations, financial results, cash-resource commentary, medical-conference abstracts, access-related research, investor conference participation and Nasdaq inducement equity grants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Dyne Therapeutics, Inc. (DYN) announced that DYNE-251, its investigational therapy for Duchenne muscular dystrophy (DMD), received FDA orphan drug and rare pediatric disease designations. This marks a significant step as DYNE-251 undergoes evaluation in the Phase 1/2 DELIVER clinical trial. The trial aims to enroll 46 males aged 4 to 16 with DMD mutations suitable for exon 51 skipping. Initial data is expected in the second half of 2023, focusing on safety and dystrophin levels. DYNE-251 uses a novel delivery method targeting muscle cells, showing promising results in preclinical studies, including a favorable safety profile and effective exon skipping.